Literature DB >> 32537180

Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014.

Quinn T Ostrom1,2, Gabrielle Truitt1,3,4, Haley Gittleman1,4,5, Daniel J Brat6, Carol Kruchko1, Reda Wilson7, Jill S Barnholtz-Sloan1,4,5.   

Abstract

BACKGROUND: The majority of reported cancer survival statistics in the United States are generated using the National Cancer Institute's publicly available Surveillance, Epidemiology, and End Results (SEER) data, which prior to 2019 represented 28% of the US population (now 37%). In the case of rare cancers or special subpopulations, data sets based on a larger portion of the US population may contribute new insights into these low-incidence cancers. The purpose of this study is to characterize the histology-specific survival patterns for all primary malignant and nonmalignant primary brain tumors in the United States using the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR).
METHODS: Survival data were obtained from the NPCR (includes data from 39 state cancer registries, representing 81% of the US population). Relative survival rates (RS) with 95% CI were generated using SEER*Stat 8.3.5 from 2004 to 2014 by behavior, histology, sex, race/ethnicity, and age at diagnosis.
RESULTS: Overall, there were 488 314 cases from 2004 to 2014. Overall 5-year RS was 69.8% (95% CI = 69.6%-69.9%). Five-year RS was 35.9% (95% CI = 35.6%-36.1%) for malignant and 90.2% (95% CI = 90.1%-90.4%) for nonmalignant tumors. Pilocytic astrocytoma had the longest 5-year RS (94.2%, 95% CI = 93.6%-94.6%) of all glioma subtypes, whereas glioblastoma had the shortest 5-year RS (6.1%, 95% CI = 6.0%-6.3%). Nonmalignant nerve sheath tumors had the longest 5-year RS (99.3%, 95% CI = 99.1%-99.4%). Younger age and female sex were associated with increased survival for many histologies.
CONCLUSIONS: Survival after diagnosis with primary brain tumor varies by behavior, histology, and age. Using such a database that includes more than 80% of the US population may represent national survival patterns.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  National Program of Cancer Registries (NPCR); United States; United States Cancer Statistics (USCS); brain and CNS tumors; relative survival

Year:  2019        PMID: 32537180      PMCID: PMC7274192          DOI: 10.1093/nop/npz059

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  21 in total

Review 1.  Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors.

Authors:  Carol Kruchko; Haley Gittleman; Jennifer Ruhl; Jim Hofferkamp; Elizabeth M Ward; Quinn T Ostrom; Recinda L Sherman; Sandra F Jones; Jill S Barnholtz-Sloan; Reda J Wilson
Journal:  Neurooncol Pract       Date:  2019-07-02

Review 2.  Consensus Conference on Brain Tumor Definition for registration. November 10, 2000.

Authors:  Bridget J McCarthy; Tanya Surawicz; Janet M Bruner; Carol Kruchko; Faith Davis
Journal:  Neuro Oncol       Date:  2002-04       Impact factor: 12.300

3.  Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013.

Authors:  Vishesh Khanna; Rebecca L Achey; Quinn T Ostrom; Hunter Block-Beach; Carol Kruchko; Jill S Barnholtz-Sloan; Peter M de Blank
Journal:  J Neurooncol       Date:  2017-08-21       Impact factor: 4.130

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes.

Authors:  James E Bates; Gyujae Choi; Michael T Milano
Journal:  J Neurooncol       Date:  2016-06-15       Impact factor: 4.130

6.  Intracranial Subependymoma: A SEER Analysis 2004-2013.

Authors:  Ha Son Nguyen; Ninh Doan; Michael Gelsomino; Saman Shabani
Journal:  World Neurosurg       Date:  2017-02-15       Impact factor: 2.104

7.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

8.  Pediatric neuro-oncology survival disparities in California.

Authors:  Tabitha Cooney; Paul G Fisher; Li Tao; Christina A Clarke; Sonia Partap
Journal:  J Neurooncol       Date:  2018-02-07       Impact factor: 4.130

9.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Authors:  Quinn T Ostrom; Gino Cioffi; Haley Gittleman; Nirav Patil; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-11-01       Impact factor: 12.300

10.  Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma.

Authors:  Haley Gittleman; Quinn T Ostrom; L C Stetson; Kristin Waite; Tiffany R Hodges; Christina H Wright; James Wright; Joshua B Rubin; Michael E Berens; Justin Lathia; James R Connor; Carol Kruchko; Andrew E Sloan; Jill S Barnholtz-Sloan
Journal:  Neurooncol Pract       Date:  2019-05-18
View more
  8 in total

1.  TRIM56 Reduces Radiosensitization of Human Glioblastoma by Regulating FOXM1-Mediated DNA Repair.

Authors:  Yun Dong; Yiping Xiong; Duanyang Zhou; Min Yao; Xiao Wang; Wenchuan Bi; Jian Zhang
Journal:  Mol Neurobiol       Date:  2022-06-13       Impact factor: 5.682

2.  Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study.

Authors:  Mario Caccese; Matteo Simonelli; Veronica Villani; Simona Rizzato; Tamara Ius; Francesco Pasqualetti; Marco Russo; Roberta Rudà; Rosina Amoroso; Luisa Bellu; Roberta Bertorelle; Francesco Cavallin; Angelo Dipasquale; Mariantonia Carosi; Stefano Pizzolitto; Daniela Cesselli; Pasquale Persico; Beatrice Casini; Matteo Fassan; Vittorina Zagonel; Giuseppe Lombardi
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

Review 3.  Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?

Authors:  William Echavidre; Vincent Picco; Marc Faraggi; Christopher Montemagno
Journal:  Pharmaceutics       Date:  2022-05-13       Impact factor: 6.525

4.  Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.

Authors:  Maria-Magdalena Georgescu; Mohammad Zahidul Islam; Yan Li; James Traylor; Anil Nanda
Journal:  Acta Neuropathol Commun       Date:  2021-04-14       Impact factor: 7.801

5.  Circadian Gene cry Controls Tumorigenesis through Modulation of Myc Accumulation in Glioblastoma Cells.

Authors:  Patricia Jarabo; Carmen de Pablo; Amanda González-Blanco; Sergio Casas-Tintó
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

6.  Phlomis fruticosa L. exerts in vitro antineurodegenerative and antioxidant activities and induces prooxidant effect in glioblastoma cell line.

Authors:  Dejan Stojkovic; Danijela Drakulic; Maria Inês Dias; Gokhan Zengin; Lillian Barros; Marija Ivanov; Uroš Gašic; Nemanja Rajcevic; Milena Stevanovic; Isabel C F R Ferreira; Marina Sokovic
Journal:  EXCLI J       Date:  2022-02-14       Impact factor: 4.068

7.  Immunoexpression of p62/SQSTM1/Sequestosome-1 in human primary and recurrent IDH1/2 wild-type glioblastoma: A pilot study.

Authors:  Antonio Ieni; Cristina Pizzimenti; Giuseppe Broggi; Rosario Caltabiano; Antonino Germanò; Giuseppe Maria Vincenzo Barbagallo; Paolo Vigneri; Giuseppe Giuffrè; Giovanni Tuccari
Journal:  Oncol Lett       Date:  2022-08-11       Impact factor: 3.111

8.  CD9- and CD81-positive extracellular vesicles provide a marker to monitor glioblastoma cell response to photon-based and proton-based radiotherapy.

Authors:  Sara Jennrich; Martin Pelzer; Tobias Tertel; Benjamin Koska; Melanie Vüllings; Basant Kumar Thakur; Verena Jendrossek; Beate Timmermann; Bernd Giebel; Justine Rudner
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.